Preclinical Evaluation of a New Anti-COVID-19 Intravenous Immunoglobulin

Preclinical Evaluation of a New Anti-COVID-19 Intravenous Immunoglobulin

Introduction. Using of immunoglobulins containing SARS-CoV-2 neutralizing antibodies may be an effective and safe tool for COVID-19 treatment. An intravenous immunoglobulin COVID-globulin from donor blood plasma containing SARS-CoV-2 neutralizing antibodies was developed at Joint-Stock Company Nacim...

Full description

Saved in:
Bibliographic Details
Main Authors: A. M. Nikolaeva, A. V. Ivanov, T. I. Smolyanova, M. V. Razumikhin, O. V. Belyakova, E. G. Shilova, N. R. Selezneva, T. V. Vyaznikova, A. I. Semicheva, E. I. Sakanyan
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2023-02-01
Series:Разработка и регистрация лекарственных средств
Subjects:
intravenous immunoglobulin
preclinical studies
toxicity
safety
coronavirus infection
covid-19
Online Access:https://www.pharmjournal.ru/jour/article/view/1446
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1446

Similar Items